These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12424559)

  • 1. Treatment of hepatitis B.
    Wai CT; Lok AS
    J Gastroenterol; 2002; 37(10):771-8. PubMed ID: 12424559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Chronic hepatitis B virus infection].
    Trifan A; Stanciu C
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(1):19-27. PubMed ID: 14755965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients.
    Sarin SK; Kumar M; Kumar R; Kazim SN; Guptan RC; Sakhuja P; Sharma BC
    Am J Gastroenterol; 2005 Nov; 100(11):2463-71. PubMed ID: 16279901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
    Liaw YF
    Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial.
    Karabay O; Tamer A; Tahtaci M; Vardi S; Celebi H
    J Microbiol Immunol Infect; 2005 Aug; 38(4):262-6. PubMed ID: 16118673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
    Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
    Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quantitative detection of intrahepatic hepatitis B virus DNA in patients with chronic hepatitis B].
    Lu H; Ma LX; Xu WS; Zhang HY; Yu LJ; Duan HY
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):173-5. PubMed ID: 12681068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of lamivudine in patients with hepatitis B e antigen-negative chronic liver diseases].
    Jeong Id; Park NH; Kim BC; Park JH; Seo KW; Kim DH; Joo KR; Kim DH
    Taehan Kan Hakhoe Chi; 2003 Jun; 9(2):69-78. PubMed ID: 12824746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An extended two-year trial of lamivudine in Chinese patients with chronic hepatitis B.
    Yao G; Cui Z; Wang B; Yao J; Zeng M
    Chin Med J (Engl); 2002 Dec; 115(12):1814-8. PubMed ID: 12622930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history and prognosis of hepatitis B.
    Fattovich G
    Semin Liver Dis; 2003 Feb; 23(1):47-58. PubMed ID: 12616450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and treatment of chronic hepatitis B: an update.
    Morgan M; Park W; Keeffe EB
    Minerva Gastroenterol Dietol; 2007 Mar; 53(1):25-41. PubMed ID: 17415343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Chronic hepatitis B treated with domestic manufactured lamivudine in 2200 patients: a phase IV study].
    Yao GB; Cui ZY; Yao JL; Zhang DF; Ji NX; Huang Y
    Zhonghua Gan Zang Bing Za Zhi; 2003 Feb; 11(2):103-8. PubMed ID: 12648409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of antiviral treatment on intrahepatic HBV DNA and histology in HBeAg -positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Zheng JJ; Chen XY; Han ZH; Chen Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):54-6. PubMed ID: 18414702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to interferon-alpha in chronic hepatitis B patients with and without precore mutant strain and effects on HBsAg titers.
    Akhan SC; Yulugkural Z; Vahaboglu H
    Chemotherapy; 2007; 53(6):402-6. PubMed ID: 17934260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of chronic hepatitis B virus infection: a new era of disease control.
    Farrell GC; Teoh NC
    Intern Med J; 2006 Feb; 36(2):100-13. PubMed ID: 16472264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.